SLXN

NASD Silexion Therapeutics Corp
Oct 1, 2026 · 6:23 AM ET LAST TRADE Market Closed

$0.2715 ↓ -0.0058 (-2.09%) Trading Down from the previous close of $0.2773

YTD change
-98.59%
vs 20-day SMA
-22.68%
vs 200-day SMA
-97.03%

Price ranges

Previous day
$0.2560 $0.2773
open $0.2685 close $0.2773
+$0.0088 (+3.28%)
Today
$0.0000 $0.0000
$0.2715
Past week
$0.2362 $0.4000
from $0.3153 now $0.2715
-$0.0438 (-13.89%)
Past month
$0.2362 $0.6303
from $0.3701 now $0.2715
-$0.0986 (-26.64%)
This year
$0.2310 $19.2000
from $19.2000 now $0.2715
-$18.9285 (-98.59%)

Price & Performance

-0.94 (-77.27%) / 6M

$-0.1313$1.70$3.54$5.37Apr 1Jul 1Sep 30

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 100.0% away from all-time highs of $6,277.5000
  • SLXN is down 99% since the beginning of the year
  • SLXN is down 99% over the past 12 months
  • SLXN is down 27% over the past 1 month
  • 2% of all SLXN investors are betting against SLXN

SLXN reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -92.7%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-5.17
Earnings momentum +43.2% Quarterly EPS growth
Quarterly change +43.2%

Valuation

P/E ratio N/A
Enterprise value $-657397.0
Beta -0.13

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$2.3M
Debt$1.4K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Market cap $3.9M

Silexion Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery and development of treatments for KRAS-driven cancers. The company was founded on November 30, 2008 and is headquartered in in Modiin, Israel.

Competitor comparison

No peer group available for this symbol.

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.